CASI Pharmaceuticals, Inc.
CASIF
$0.13
-$0.01-4.59%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 134.86% | -26.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 134.86% | -26.35% | |||
| Cost of Revenue | 48.97% | 11.90% | |||
| Gross Profit | 423.09% | -65.69% | |||
| SG&A Expenses | 47.97% | -13.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 41.72% | -10.55% | |||
| Operating Income | -13.76% | 4.40% | |||
| Income Before Tax | -19.85% | 18.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.85% | 18.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.85% | 18.63% | |||
| EBIT | -13.76% | 4.40% | |||
| EBITDA | -17.37% | 4.65% | |||
| EPS Basic | 29.02% | 21.39% | |||
| Normalized Basic EPS | 28.89% | -- | |||
| EPS Diluted | 29.02% | 21.39% | |||
| Normalized Diluted EPS | 28.89% | -- | |||
| Average Basic Shares Outstanding | 68.84% | 3.50% | |||
| Average Diluted Shares Outstanding | 68.84% | 3.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||